Rani Therapeutics Holdings Inc (NASDAQ:RANI) price on Friday, June 13, fall -6.28% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $0.53.
A look at the stock’s price movement, the close in the last trading session was $0.56. Turning to its 52-week performance, $4.45 and $0.46 were the 52-week high and 52-week low respectively. Overall, RANI moved -5.66% over the past month.
Rani Therapeutics Holdings Inc’s market cap currently stands at around $30.22 million, with investors looking forward to this quarter’s earnings report slated for in July.
3 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 3 recommend RANI as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
RANI’s current price about -12.58% and -38.71% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 32.04, while 7-day volatility ratio is 3.29% and 5.50% in the 30-day chart. Further, Rani Therapeutics Holdings Inc (RANI) has a beta value of 0.00, and an average true range (ATR) of 0.07. Analysts have given the company’s stock an average 52-week price target of $10, forecast between a low of $9 and high of $28. Looking at the price targets, the low is -1598.11% off current price level while to achieve the yearly target high, price needs to move -5183.02%. Nonetheless, investors will most likely welcome a -1786.79% jump to $10 which is the analysts’ median price.
If we refocus on Rani Therapeutics Holdings Inc (NASDAQ:RANI), historical trading data shows that trading volumes averaged 413.23K over the past 3 months. The company’s latest data on shares outstanding shows there are 33.57 million shares.
The 32.12% of Rani Therapeutics Holdings Inc’s shares are in the hands of company insiders while institutional holders own 7.34% of the company’s shares. Current price change has pushed the stock -61.66% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the RANI stock continues to rise going into the next quarter.
